

PRESSURE BIOSCIENCES INC  
Form 10-Q  
May 15, 2012

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

(Mark One)

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2012 or

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 0-21615

PRESSURE BIOSCIENCES, INC.  
(Exact Name of Registrant as Specified in its Charter)

Massachusetts  
(State or Other Jurisdiction of  
Incorporation or Organization)

04-2652826  
(I.R.S. Employer  
Identification No.)

14 Norfolk Avenue  
South Easton, Massachusetts  
(Address of Principal Executive Offices)

02375

(Zip Code)

(508) 230-1828

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting

Edgar Filing: PRESSURE BIOSCIENCES INC - Form 10-Q

company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act).

Yes  No

The number of shares outstanding of the Issuer’s common stock as of May 10, 2012 was 10,356,449.

---

TABLE OF CONTENTS

	Page
PART I - FINANCIAL INFORMATION	
Item 1. Financial Statements (Unaudited)	
Consolidated Balance Sheets as of March 31, 2012 and December 31, 2011	3
Consolidated Statements of Operations for the Three Months Ended March 31, 2012 and 2011	4
Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2012 and 2011	5
Notes to Consolidated Financial Statements	6
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	23
Item 4. Controls and Procedures	29
PART II - OTHER INFORMATION	
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	30
Item 6. Exhibits	31

---

## PART I. FINANCIAL INFORMATION

## Item 1. Financial Statements

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY  
CONSOLIDATED BALANCE SHEETS

ASSETS	March 31, 2012 (Unaudited)	December 31, 2011 (Audited)
<b>CURRENT ASSETS</b>		
Cash and cash equivalents	\$15,492	\$222,775
Accounts receivable, net of allowances of \$9,600 at March 31, 2012 and December 31, 2011	203,998	269,237
Inventories	1,021,295	1,069,013
Prepaid income taxes	8,181	4,739
Prepaid expenses and other current assets	269,828	143,591
Total current assets	1,518,794	1,709,355
PROPERTY AND EQUIPMENT, NET	72,006	89,171
<b>OTHER ASSETS</b>		
Deposits	6,472	6,472
Intangible assets, net	121,604	133,762
<b>TOTAL ASSETS</b>	<b>\$1,718,876</b>	<b>\$1,938,760</b>
<b>LIABILITIES AND STOCKHOLDERS' DEFICIT</b>		
<b>CURRENT LIABILITIES</b>		
Accounts payable	\$1,129,515	\$890,676
Accrued employee compensation	224,766	180,437
Accrued professional fees and other	270,792	247,738
Deferred revenue	37,358	36,669
Promissory note	150,000	150,000
Convertible debt, net of unamortized discount of \$0 at March 31, 2012 and \$17,088 as of December 31, 2011	56,139	394,912
Warrant derivative liabilities	478,565	436,553
Total current liabilities	2,347,135	2,336,985
<b>LONG TERM LIABILITIES</b>		
Deferred revenue	7,579	10,111
<b>TOTAL LIABILITIES</b>	<b>2,354,714</b>	<b>2,347,096</b>
<b>COMMITMENTS AND CONTINGENCIES (Note 4)</b>		
<b>STOCKHOLDERS' DEFICIT</b>		
Series C convertible preferred stock, \$.01 par value; 88,098 shares authorized; 88,098 shares issued and outstanding on March 31, 2012 and December 31, 2011 (Liquidation value of \$1,101,225)	881	881
Series D convertible preferred stock, \$.01 par value; 850 shares authorized; 300 shares issued and outstanding on March 31, 2012 and 743 shares issued and	3	7

Edgar Filing: PRESSURE BIOSCIENCES INC - Form 10-Q

outstanding on December 31, 2011 (Liquidation value of \$300,000)

Common stock, \$.01 par value; 20,000,000 shares authorized; 8,499,898 shares issued and outstanding on March 31, 2012 and 6,723,993 shares issued and outstanding on December 31, 2011	84,999	67,240
Warrants to acquire preferred stock and common stock	2,510,504	2,203,101
Additional paid-in capital	14,358,536	13,823,875
Accumulated deficit	(17,590,761)	(16,503,440)
Total stockholders' deficit	(635,838 )	(408,336 )
<b>TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</b>	<b>\$1,718,876</b>	<b>\$1,938,760</b>

The accompanying notes are an integral part of these consolidated financial statements

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY  
CONSOLIDATED STATEMENTS OF OPERATIONS  
(UNAUDITED)

	For the Three Months Ended March 31,	
	2012	2011
<b>Revenue:</b>		
PCT products, services, other	\$ 164,772	\$ 180,643
Grant revenue	140,889	-
<b>Total revenue</b>	<b>305,661</b>	<b>180,643</b>
<b>Costs and expenses:</b>		
Cost of PCT products and services	78,194	78,929
Research and development	271,611	218,965
Selling and marketing	238,092	303,839
General and administrative	682,346	412,529
<b>Total operating costs and expenses</b>	<b>1,270,243</b>	<b>1,014,262</b>
<b>Operating loss</b>	<b>(964,582 )</b>	<b>(833,619 )</b>
<b>Other (expense) income:</b>		
Interest (expense) income	(56,313 )	254
Change in fair value of warrant derivative liability	(42,012 )	-
<b>Total other (expense) income</b>	<b>(98,325 )</b>	<b>254</b>
<b>Net loss</b>	<b>(1,062,907)</b>	<b>(833,365 )</b>
Accrued and deemed dividends on convertible preferred stock	(24,414 )	(133,090 )
<b>Net loss applicable to common shareholders</b>		